Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-CART-027 in Recurrent or Progressive Grade 4 Glioma
NCT07384390Phase 1Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of TH-CART-027 in glioma, sponsored by Tongji Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 6 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
TH-CART-027
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07384390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384390.